Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$34.00
+4.2%		$35.85
$22.24
▼
$46.00
$2.03B0.581.05 million shs216,240 shs
CG Oncology, Inc. stock logo
CGON
CG Oncology
$78.88
+0.8%		$71.69
$25.25
▼
$80.97
$7.00B0.231.13 million shs177,003 shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$36.72
+1.4%		$38.55
$11.60
▼
$43.73
$6.38B0.382.20 million shs157,334 shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$55.58
-0.8%		$53.14
$26.76
▼
$59.30
$8.51B1.622.22 million shs653,710 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-1.36%-2.94%-10.23%+15.21%-15.88%
CG Oncology, Inc. stock logo
CGON
CG Oncology
-1.98%+1.45%+12.85%+26.40%+190.60%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-1.36%-4.33%-8.88%+6.75%+198.93%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
+3.21%+13.66%-0.05%+40.98%+90.25%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$34.00
+4.2%		$35.85
$22.24
▼
$46.00
$2.03B0.581.05 million shs216,240 shs
CG Oncology, Inc. stock logo
CGON
CG Oncology
$78.88
+0.8%		$71.69
$25.25
▼
$80.97
$7.00B0.231.13 million shs177,003 shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$36.72
+1.4%		$38.55
$11.60
▼
$43.73
$6.38B0.382.20 million shs157,334 shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$55.58
-0.8%		$53.14
$26.76
▼
$59.30
$8.51B1.622.22 million shs653,710 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-1.36%-2.94%-10.23%+15.21%-15.88%
CG Oncology, Inc. stock logo
CGON
CG Oncology
-1.98%+1.45%+12.85%+26.40%+190.60%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-1.36%-4.33%-8.88%+6.75%+198.93%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
+3.21%+13.66%-0.05%+40.98%+90.25%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
2.40
Hold$41.2526.38% Upside
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.71
Moderate Buy$83.186.33% Upside
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.85
Moderate Buy$49.4036.35% Upside
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.44
Hold$63.0012.48% Upside

Current Analyst Ratings Breakdown

Latest AGIO, TGTX, COGT, and CGON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$52.00 ➝ $55.00
8/12/2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $52.00
8/7/2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$31.00 ➝ $34.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$81.00 ➝ $79.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$82.00 ➝ $85.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$82.00 ➝ $85.00
8/7/2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$65.00 ➝ $72.00
8/4/2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$78.00
7/31/2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$46.00 ➝ $52.00
7/31/2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$41.00 ➝ $39.00
7/30/2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$52.00 ➝ $55.00
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$54.03M36.07N/AN/A$20.46 per share1.60
CG Oncology, Inc. stock logo
CGON
CG Oncology
$4.04M1,716.41N/AN/A$9.33 per share8.38
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/A$3.84 per shareN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$616.29M13.91$2.89 per share19.37$4.08 per share13.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$412.78M-$7.01N/AN/AN/A-418.24%-35.67%-33.06%10/29/2026 (Estimated)
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.69N/AN/AN/A-3,602.68%-25.20%-23.98%11/13/2026 (Estimated)
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$328.94M-$2.16N/AN/AN/AN/A-84.47%-47.72%11/6/2026 (Estimated)
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$447.18M$2.7420.4421.142.3355.22%73.49%34.14%11/2/2026 (Estimated)

Latest AGIO, TGTX, COGT, and CGON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.5550-$0.52+$0.0350-$0.52$0.00 millionN/A
8/6/2026Q2 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.6642-$0.90-$0.2359-$0.90$0.36 million$1.16 million
8/3/2026Q2 2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.3057$0.05-$0.2557$0.05$229.77 million$240.34 million
7/30/2026Q2 2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.65-$1.69-$0.04-$1.69$26.40 million$44.75 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/AN/AN/AN/AN/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
10.22
9.79
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
22.22
22.20
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.48
13.57
13.57
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1.23
4.27
3.72

Institutional Ownership

CompanyInstitutional Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
58.58%

Insider Ownership

CompanyInsider Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
5.40%
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
6.59%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
8.87%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
39059.70 million56.48 millionOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6188.64 million84.39 millionOptionable
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
80173.52 million162.09 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
290153.07 million139.49 millionOptionable

Recent News About These Companies

TGTX stock outperforms 95% of stocks. Here's why.
August 24 at 3:58 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/tgtx-stock-outperforms-95-of-stocks-here-s-why/ar-AA2aPDus
Great Lakes Advisors LLC Invests $1.11 Million in TG Therapeutics, Inc. $TGTX
August 23 at 5:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-great-lakes-advisors-llc-invests-111-million-in-tg-therapeutics-inc-tgtx-2026-08-23/
235,481 Shares in TG Therapeutics, Inc. $TGTX Bought by Deutsche Bank AG
August 23 at 3:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-235481-shares-in-tg-therapeutics-inc-tgtx-bought-by-deutsche-bank-ag-2026-08-23/
Stock Traders Purchase Large Volume of TG Therapeutics Call Options (NASDAQ:TGTX)
August 23 at 1:20 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30977214
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
August 22 at 10:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4939338-tg-therapeutics-briumvis-growth-attracts-buyout-rumors
BlackRock Inc. Takes Position in TG Therapeutics, Inc. $TGTX
August 22 at 3:21 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-takes-position-in-tg-therapeutics-inc-tgtx-2026-08-22/
TGTX stock alert: What to know as takeover rumors swirl around TG Therapeutics
August 21, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/tgtx-stock-alert-what-to-know-as-takeover-rumors-swirl-around-tg-therapeutics/ar-AA2aGiMs
TG Therapeutics (NASDAQ:TGTX) Trading 10.1% Higher - Should You Buy?
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tg-therapeutics-nasdaqtgtx-trading-101-higher-should-you-buy-2026-08-21/
TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tg-therapeutics-target-of-unusually-large-options-trading-nasdaqtgtx-2026-08-21/
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tg-therapeutics-conference-908-devices-bets-on-handheld-drug-chemical-detection-2026-08-17/
Bank of America Corp DE Purchases 610,195 Shares of TG Therapeutics, Inc. $TGTX
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-purchases-610195-shares-of-tg-therapeutics-inc-tgtx-2026-08-13/
Assenagon Asset Management S.A. Lowers Stock Position in TG Therapeutics, Inc. $TGTX
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-lowers-stock-position-in-tg-therapeutics-inc-tgtx-2026-08-13/
TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript
August 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tg-therapeutics-tgtx-q2-2026-013254405.html
TG Therapeutics, Inc. $TGTX Position Trimmed by First Trust Advisors LP
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tg-therapeutics-inc-tgtx-position-trimmed-by-first-trust-advisors-lp-2026-08-10/
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Brokerages
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tg-therapeutics-inc-nasdaqtgtx-receives-consensus-rating-of-hold-from-brokerages-2026-08-08/
JPMorgan Chase & Co. Issues Positive Forecast for TG Therapeutics (NASDAQ:TGTX) Stock Price
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jpmorgan-chase-co-issues-positive-forecast-for-tg-therapeutics-nasdaqtgtx-stock-price-2026-08-07/
California State Teachers Retirement System Increases Stock Position in TG Therapeutics, Inc. $TGTX
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-increases-stock-position-in-tg-therapeutics-inc-tgtx-2026-08-06/
HC Wainwright Expects Higher Earnings for TG Therapeutics
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-expects-higher-earnings-for-tg-therapeutics-2026-08-05/
TG Therapeutics, Inc. $TGTX Shares Purchased by Sei Investments Co.
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tg-therapeutics-inc-tgtx-shares-purchased-by-sei-investments-co-2026-08-05/
Empowered Funds LLC Increases Stake in TG Therapeutics, Inc. $TGTX
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-empowered-funds-llc-increases-stake-in-tg-therapeutics-inc-tgtx-2026-08-05/
TG Therapeutics, Inc. $TGTX Stock Holdings Boosted by Dimensional Fund Advisors LP
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tg-therapeutics-inc-tgtx-stock-holdings-boosted-by-dimensional-fund-advisors-lp-2026-08-05/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
NVIDIA and OpenAI logos displayed on a computer chip against a background of data center servers.
NVIDIA’s OpenAI Backstop Puts AI Financing Risk in Focus
By Jeffrey Neal Johnson | July 29, 2026
Agios Pharmaceuticals stock logo

Agios Pharmaceuticals NASDAQ:AGIO

$33.99 +1.36 (+4.15%)
As of 11:38 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$78.88 +0.65 (+0.82%)
As of 11:38 AM Eastern
This is a fair market value price provided by Massive. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:COGT

$36.72 +0.49 (+1.36%)
As of 11:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$55.58 -0.44 (-0.78%)
As of 11:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas